市场调查报告书
商品编码
1422083
全球智慧胰岛素笔市场评估:按类型、按适应症、按用途、按产品、按连接性、按最终用户、按分销渠道、按地区、机会、预测(2017-2031)Smart Insulin Pens Market Assessment, By Type, By Indication, By Usability, By Product, By Connectivity, By End-user, By Distribution Channel, By Region, By Opportunities and Forecast, 2017-2031F |
预计2023年全球智慧胰岛素笔市场规模将达到5,140万美元,2031年将达到1.2909亿美元,2024-2031年预测期间复合年增长率为12.2%。Masu。 糖尿病盛行率的增加、血糖控制的改善、患者便利性的提高、技术的持续进步、对远距医疗的重视、意识的提高、用药错误风险的最小化、潜在的医疗成本节省等。众多因素正在推动全球智慧胰岛素笔市场的发展。
全球智慧胰岛素笔市场代表了糖尿病管理的重大飞跃。 这些突破性的设备彻底改变了糖尿病患者的胰岛素给药流程,提供更高的准确性、便利性和数据驱动的见解,以改善整体福祉和生活品质。 全球糖尿病流行以及对高效且易于使用的糖尿病管理工具日益增长的需求正在推动全球智慧胰岛素笔市场的扩张。 医疗保健提供者和患者越来越认识到这些设备改善胰岛素治疗的潜力,从而实现更有效的血糖控制并减少与糖尿病相关的长期併发症。
随着製造商技术进步并推出日益复杂的功能和连接选项,全球智慧胰岛素笔市场将持续成长。 智慧胰岛素笔采用的技术可促进自动、准确的剂量计算,减少胰岛素注射过程中人为错误的可能性。 这些设备通常与智慧型手机应用程式建立无线连接,允许用户追踪胰岛素剂量历史、血糖水平和其他重要数据。 这为改善糖尿病管理和提高患有这种慢性疾病的人的独立性提供了广阔的前景。
人们对使用智慧方法监测和控製糖尿病的意识不断增强,导致全球智慧胰岛素笔市场显着成长。 糖尿病照护正在从传统的面对面就诊转向视讯就诊等同步远距医疗方法,以及主要由市场新创公司提供的越来越多的非同步数位医疗服务。 过去几十年来,胰岛素笔的使用在美国稳步增加,并已成为第 1 型糖尿病 (T1D) 和第 2 型糖尿病 (T2D) 患者的首选胰岛素给药方法。 目前,胰岛素笔在商业保险个人中占据主导地位。 患者选择胰岛素笔是因为它们比胰岛素瓶或註射器方法更令人满意且更容易使用。 这些笔提供卓越的剂量准确性,从而提高胰岛素依从性。 此外,胰岛素笔的使用降低了 HbA1c 水平,最大限度地减少了高血糖,并显示出更好的血糖控制。 儘管初始成本较高,胰岛素笔可降低总医疗成本,从而减少住院治疗、糖尿病相关住院治疗以及高血糖相关医疗保健利用率。
技术创新改变了全球智慧胰岛素笔市场的格局。 这些发展包括准确的剂量计算、即时智慧型手机数据整合、用户友好的介面等等。 智慧胰岛素笔的发展为人们提供了管理健康的有效手段,最终提高了福祉并提高了生活品质。 例如,2023 年 3 月,自动胰岛素输送领域的先驱 Diabeloop 宣布与全球着名医疗保健公司诺和诺德建立合作关係。 两家公司的工作重点是推动包含连网胰岛素笔的互通性策略。 该协议涵盖Diabeloop 的自学习MDI(每日多次注射)治疗演算法、DBL-4pen(TM) 和可重复使用的连接设备,例如诺和诺德的NovoPen(R) 6 和NovoPen Echo(R) Plus ,还包括胰岛素笔集成。
本报告研究分析了全球智慧胰岛素笔市场,提供市场规模和预测、市场动态、主要参与者现状和前景等。
Global Smart Insulin Pens Market size was valued at USD 51.4 million in 2023, expected to reach USD 129.09 million in 2031 with a CAGR of 12.2% for the forecast period between 2024 and 2031F. Numerous factors are propelling the global smart insulin pens market forward, including the increasing prevalence of diabetes, better management of glycaemic levels, increased patient convenience, ongoing technological progress, a heightened emphasis on telehealth, growing awareness, minimized medication error risk, and potential healthcare cost reductions.
The global smart insulin pens market signifies a significant leap forward in diabetes management. These groundbreaking devices have revolutionized the insulin administration process for people with diabetes, providing them with improved accuracy, convenience, and data-driven insights to improve their overall well-being and quality of life. The escalating global diabetes prevalence and the growing need for efficient and user-friendly diabetes management tools have fuelled the expansion of the global smart insulin pens market. Both healthcare providers and patients are increasingly acknowledging the potential of these devices to improve insulin therapy, leading to more effective glycaemic control and a reduction in the long-term complications associated with diabetes.
With the evolution of technology and the introduction of increasingly sophisticated features and connectivity choices by manufacturers, the global smart insulin pens market is positioned for ongoing growth. Smart insulin pens are furnished with technology that facilitates automated and precise dose calculations, diminishing the potential for human errors during insulin administration. These devices frequently establish wireless connections with smartphone applications, enabling users to track their insulin dosing history, blood glucose levels, and other vital data. This presents a promising outlook for improved diabetes management and increased independence for individuals with this chronic condition.
The increased awareness of using smart methods to monitor and control diabetes has led to significant growth in the global smart insulin pens market. Diabetes care is transitioning from traditional in-person office visits to synchronous telehealth methods, such as video consultations, and increasingly, asynchronous digital healthcare services, primarily provided by emerging players in the market. In the United States, the utilization of insulin pens has witnessed a consistent rise over the past few decades, becoming the preferred mode of insulin delivery for both type 1 diabetes (T1D) and type 2 diabetes (T2D) patients. Insulin pens now dominate the market among commercially insured individuals. Patients opt for insulin pens due to their high satisfaction levels and user-friendliness compared to insulin vial and syringe methods. These pens offer superior dose accuracy, leading to improved insulin adherence. Moreover, insulin pen usage has demonstrated better glycaemic controls, reducing HbA1c levels and minimizing hyperglycemia. Despite initial higher costs, insulin pens translate into lower total healthcare expenses, resulting in fewer hospitalizations, diabetes-related admissions, and instances of hyperglycemia-associated healthcare utilization for users.
Innovations in technology have transformed the realm of the global smart insulin pens market. These developments include precise dose computations, immediate smartphone data integration, and user-friendly interfaces. The evolution of smart insulin pens provides individuals with efficient means of managing their health, ultimately resulting in enhanced well-being and a better quality of life. For example, in March 2023, Diabeloop, a trailblazer in Automated Insulin Delivery, revealed a partnership with Novo Nordisk, a prominent global healthcare firm. Their joint effort focuses on advancing an interoperability strategy incorporating connected insulin pens. The agreement involves the integration of Diabeloop's self-learning algorithm for Multiple Daily Injections (MDI) therapy, DBL-4pen™, with Novo Nordisk's connected and reusable insulin pens, including NovoPen® 6 and NovoPen Echo® Plus.
Government programs focusing on smart insulin pens are pivotal in tackling the worldwide diabetes crisis and improving the well-being of those afflicted with the condition. Governments efforts give a huge boost to global smart insulin pens market. These efforts reflect a forward-looking approach governments took to combat the increasing incidence of diabetes and the escalating need for cutting-edge solutions in diabetes care and management. On January 1, 2023, a notable development occurred as smart insulin pens were incorporated into Medicare Part D by the US government. This means that individuals enrolled in Medicare who rely on smart insulin pens will now have their expenses capped at a maximum of $35 per month for a one-month supply of each approved insulin product. This pivotal inclusion of smart insulin pens in Medicare Part D was mandated under the Affordable Care Act, commonly known as Obamacare. The ACA mandates Medicare to encompass specific categories of diabetes-related supplies, among them being insulin pens. Such initiatives have a large impact on the global smart insulin pens market.
The advent of Bluetooth-enabled smart insulin pens marks a substantial advancement in global smart insulin pens market. These cutting-edge tools amalgamate the precision inherent in conventional insulin pens with the capabilities of Bluetooth connectivity, presenting users with a cohesive and data-centric methodology for managing their insulin therapy. By facilitating immediate data transfer to smartphones and other suitable devices, these smart insulin pens empower individuals managing diabetes to meticulously monitor their insulin doses, oversee blood glucose levels, receive dose guidance, and seamlessly communicate vital health data with healthcare professionals. As an example, in December 2022, Biocorp, a French firm specializing in medical devices and drug delivery systems, unveiled its FDA 510(k) clearance to commercialize the Mallya smart medical device, designed to interface with insulin pens. Mallya, functioning as a smart sensor, seamlessly affixes to insulin pen injectors, effectively transforming them into connected devices via bluetooth.
Disposable smart insulin pens are reshaping diabetes management by merging the simplicity of one-time-use pens with state-of-the-art technology, ultimately influencing the global smart insulin pens market. These compact instruments come pre-filled with insulin and boast smart capabilities like dosage monitoring, reminders, and wireless connectivity. This enables users to administer insulin with accuracy while effortlessly overseeing their treatment progress. The disposability factor removes the necessity for cartridge swaps, streamlining insulin administration and boosting patient adherence. As an example, in November 2021, the French multinational pharmaceutical and healthcare company Sanofi and the Swiss multinational healthcare company Roche established a collaborative effort in France. They united their efforts to promote the utilization of a connected accessory designed for disposable insulin pens. Together, they will create an educational program for healthcare professionals, including physicians and retail pharmacists, focusing on the Biocorp product known as Mallya.
COVID-19 pandemic had a huge impact on the global smart insulin pens market. On one hand, the demand for smart insulin pens surged during the pandemic, primarily driven by the heightened vulnerability of people with diabetes to severe COVID-19 complications, given their increased susceptibility to respiratory infections. This elevated demand was fueled by the urgency for effective diabetes management to reduce hospitalization risks. Conversely, the pandemic disrupted the supply chain for smart insulin pens as production facilities and distribution networks faced closures and shipping challenges, leading to shortages in certain regions. However, despite these short-term setbacks, the long-term outlook for smart insulin pen sales remains positive. COVID-19 underscored the critical importance of effective diabetes management, shedding light on the role smart insulin pens can play in empowering individuals with diabetes to manage their condition proactively and remotely. This heightened awareness is expected to drive sustained growth in the smart insulin pens market.
Amidst the rapidly changing healthcare environment, marked by a strong emphasis on precision, connectivity, and patient-centric care, the global market for smart insulin pens is experiencing a multitude of partnerships and cooperative ventures. These endeavors frequently bring together a diverse array of stakeholders, including pharmaceutical firms, technology enterprises, startups, and healthcare providers, who combine their knowledge and resources with the goal of creating advanced smart insulin pens. These next-generation devices aim not only to enhance insulin delivery precision but also to offer users immediate data insights and the ability to remotely monitor their insulin therapy. In May 2021, Eli Lilly & Co., an American pharmaceutical company, took steps to ensure the compatibility of its forthcoming connected insulin pen system with various daily diabetes management platforms by entering into compatibility agreements with four global providers. These agreements encompass a range of offerings, such as glucose monitoring sensors, digital health solutions, and other resources provided by Roche, Dexcom, Glooko, and myDiabby Healthcare.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.